Merck KGaA (FRA:MRK) has been given a €105.00 ($129.63) target price by equities research analysts at Sanford C. Bernstein in a research report issued on Wednesday. The firm presently has a “buy” rating on the healthcare company’s stock. Sanford C. Bernstein’s price target would indicate a potential upside of 37.87% from the company’s previous close.

Several other brokerages have also recently issued reports on MRK. JPMorgan Chase & Co. set a €95.00 ($117.28) price objective on shares of Merck KGaA and gave the company a “neutral” rating in a research note on Wednesday, January 10th. UBS set a €120.00 ($148.15) price objective on shares of Merck KGaA and gave the company a “buy” rating in a research note on Monday, January 8th. Kepler Capital Markets set a €115.00 ($141.98) price objective on shares of Merck KGaA and gave the company a “buy” rating in a research note on Wednesday, January 17th. Warburg Research set a €115.00 ($141.98) price objective on shares of Merck KGaA and gave the company a “buy” rating in a research note on Wednesday, December 13th. Finally, Goldman Sachs set a €100.00 ($123.46) price objective on shares of Merck KGaA and gave the company a “neutral” rating in a research note on Wednesday, November 29th. Twelve investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of €100.55 ($124.13).

How to Become a New Pot Stock Millionaire

MRK stock opened at €76.16 ($94.02) on Wednesday. The stock has a market cap of $10,070.00 and a price-to-earnings ratio of 12.74. Merck KGaA has a 12 month low of €76.60 ($94.57) and a 12 month high of €115.00 ($141.98).

TRADEMARK VIOLATION WARNING: “Merck KGaA (MRK) Given a €105.00 Price Target by Sanford C. Bernstein Analysts” was first reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.watchlistnews.com/merck-kgaa-mrk-given-a-105-00-price-target-by-sanford-c-bernstein-analysts-2/1958818.html.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.